Burgdorf – Hanmi Pharmaceutical Co., Ltd. has three biotechnology proteins in its project portfolio that are in various stages of development and approval. Ypsomed signs comprehensive master agreement with the South Korean Hanmi Pharmaceutical Co., Ltd. for pen systems and autoinjectors for three long-acting biologics.
The projects include a GLP-1, a once weekly insulin and a combination product for the treatment of obesity and diabetes. According to Gwan-sun Lee, CEO of Hanmi Pharmaceutical Co., Ltd., the company aspires to provide patients worldwide with the best therapy using the most user-friendly injection systems. This was a decisive factor in the South Korean pharmaceutical company's choice of Ypsomed as supplier of high quality injection systems.